What is Mercy Bioanalytics?
Mercy BioAnalytics is dedicated to reducing suffering and mortality by pioneering the early detection of cancer. The company leverages advanced nanotechnology, specifically extracellular vesicles (EVs) abundant in blood, to identify signals from parent cells. This innovative approach shows substantial promise for detecting cancers, such as ovarian and lung, at their earliest, most treatable stages. The company's strategic focus on these difficult-to-diagnose cancers positions it as a key player in the diagnostic biotechnology sector, aiming to transform patient outcomes through timely intervention.
How much funding has Mercy Bioanalytics raised?
Mercy Bioanalytics has raised a total of $100M across 2 funding rounds:
Series A
$41M
Series B
$59M
Series A (2023): $41M with participation from Sozo Ventures, Novalis LifeSciences, iSelect Fund Management, and Hatteras Venture Partners
Series B (2025): $59M led by Hologic, Novalis Trust, Portfolia, Bruker Scientific, BrightEdge - American Cancer Society, Avestria Ventures Management, Xontogeny, iSelect Fund Management, Labcorp, and Sozo Ventures
Key Investors in Mercy Bioanalytics
Sozo Ventures
Sozo Ventures is an expansion-stage VC firm focused on connecting ambitious entrepreneurial teams with advanced customers globally. They invest in category leaders across AI/IoT, enterprise cloud, big data, e-commerce, fintech, and healthcare IT, with a presence in Tokyo to bridge Asian enterprises and US startups.
Novalis LifeSciences
Novalis LifeSciences is a boutique investment and advisory firm specializing in the Life Science industry, providing direct investments and advisory services for companies in life science tools, diagnostics, and biopharma therapeutics. They manage $500M across three funds.
iSelect Fund Management
iSelect Fund is a venture capital firm focused on investments at the intersection of food, health, and AgTech, aiming to address global challenges in nutrition and healthcare through innovative companies.
What's next for Mercy Bioanalytics?
With the recent infusion of capital, Mercy BioAnalytics is poised to accelerate its research and development initiatives, potentially expanding its diagnostic capabilities to a wider range of cancers. The substantial enterprise-level backing suggests a strategic push towards clinical validation, regulatory approvals, and eventual commercialization. This financing will likely fuel the scaling of operations, enhance its technological platform, and strengthen its market presence, further solidifying its role in advancing early cancer detection technologies and improving global health outcomes.
See full Mercy Bioanalytics company page
